12月22日，据翰森制药公众号，近日，《中华内科杂志》发布《国家基层糖尿病防治管理指南（2025）》（以下简称指南），旨在推动基层糖尿病健康管理工作的规范化。翰森制药首个中国原研GLP-1RA周制剂孚来美®（聚乙二醇洛塞那肽注射液）被纳入指南，这是继2022年版之后再度获得这一国家级重磅指南的认可。据介绍，近年来，孚来美®发表了一系列临床及基础研究证据，展现出在血糖平稳控制、心脑血管保护、肾脏及...
Source Link12月22日，据翰森制药公众号，近日，《中华内科杂志》发布《国家基层糖尿病防治管理指南（2025）》（以下简称指南），旨在推动基层糖尿病健康管理工作的规范化。翰森制药首个中国原研GLP-1RA周制剂孚来美®（聚乙二醇洛塞那肽注射液）被纳入指南，这是继2022年版之后再度获得这一国家级重磅指南的认可。据介绍，近年来，孚来美®发表了一系列临床及基础研究证据，展现出在血糖平稳控制、心脑血管保护、肾脏及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.